Daclizumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.

**Synonyms:** - Anti-Tac - Anti-Tac Humanized Monoclonal Antibody - Anti-Tac Monoclonal Antibody - DACLIZUMAB - Dacliximab - Dacliximab - Humanized Anti-Tac Monoclonal Antibody - Monoclonal Antibody Anti-Tac - Zenapax - daclizumab